242:
219:
116:
141:
493:
248:
147:
1544:. In consequence, they are highly stable, long-lived, unregulated, and continuously express the stimulating actions of their PDGFRA tyrosine kinase component. In consequence, cells expressing FIP1L1-PDGFRA fusion proteins differentiate and proliferate along eosinophil, other granulocyte, or T lymphocyte lineages and bearers of these mutations suffer either:
1360:. The fusion gene may produce a protein consisting of the first 233 amino acids of FIP1L1 joined to the last 523 amino acids of PDGFRA or fused proteins consisting of other FIP1L1 and PDGFRA amino acid lengths. The known FIP1L1-PDGFRA fusion proteins exhibit similar if not identical pathological activities.
1797:
fusion gene-induced diseases are suggested by the presence of morphologically abnormal or excessive numbers of myeloid or lymphoid cells in the blood or bone marrow and, with respect to the lymphoid variants, by the presence of lymphadenopathy and/or lymphoma masses; ultimately, these variants also
1647:
gene fusions occurring in ~10% of patients with hypereosinophilia as detected in developed countries. The fused gene occurs with a male/female ratio of 1.47; the reason for this male predominance is not known. The fusion gene has been found in people of all age groups but only rarely in infants and
1842:
fusion gene-induced eosinophil leukemia. Commonly, patients suffering this disease respond to low dos (e.g. 100 mg/day) Gleevec but if not attaining complete remission at this dose may require the higher dosages (up to 400/mg/day) typically used to treat CML. Acquired resistance to
Gleevec is
1737:
arbitrarily define as blood cell counts containing greater than 1.5x10/liter eosinophils that have persisted for more than 6 months. However, lower levels of eosinophil counts and/or eosinophilia with a shorter history of duration are not a counter-indication of the diagnoses. These patients also
1503:
lineage. In other cases, however, the fusion, while occurring in myeloid precursor cells, promotes proliferation and differentiation of precursor cells along the neutrophil lineage or, less commonly, occurs in lymphoid precursor cells to promote the proliferation and differentiation of precursor
1881:
gene, is located on human chromosome 17 at position q21.2 (i.e. 17q21.2), consists of 17 exons, and encodes the nuclear retinoic acid receptor alpha (RARA) protein. The RARA protein, when ligand-bound, regulates the expression of genes that are implicated in the control of development,
2036:
Wiemann S, Weil B, Wellenreuther R, Gassenhuber J, Glassl S, Ansorge W, Bocher M, Blocker H, Bauersachs S, Blum H, Lauber J, Dusterhoft A, Beyer A, Kohrer K, Strack N, Mewes HW, Ottenwalder B, Obermaier B, Tampe J, Heubner D, Wambutt R, Korn B, Klein M, Poustka A (Mar 2001).
1423:
residues to pre-mRNA. This poly-adenylyl action increases pre-mRNA's maturation and movement from the nucleus to cytoplasm while also increasing the stability of the mRNA formed from pre-mRNA: FIP1L1 is a Pre-mRNA 3'-end-processing factor.
1664:
fusion gene) and marked eosinophilia commonly complain of weakness and malaise. They may also present with or have a history of signs and/or symptoms that are due to the damaging actions of tissue-infiltrating eosinophils such as: skin
2210:
Iwasaki J, Kondo T, Darmanin S, Ibata M, Onozawa M, Hashimoto D, Sakamoto N, Teshima T (2014). "FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia".
1821:
fusion gene-induced eosinophil leukemia diseases (including a case presenting with myeloid sarcoma) have been treated with great success and long term remissions using low dosages of the tyrosine kinase inhibitor,
1498:
or in precursors to these myeloid and lymphoid progenitor cells. In the majority of instances, this fusion appears in and promotes the proliferation and differentiation of myeloid precursor cells along the
1591:
with eosinophilia has been reported. (i.e. These pathological proliferation and differentiation responses are due to the unabated activity of the fusion proteins' tyrosine kinase in
1640:
3164:"A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2, and polypyrimidine tract binding protein"
1773:
or cells with microscopically visible chromosome abnormalities. This examination may be useful in excluding other malignant diseases associated with eosinophilia such as
255:
154:
2799:"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy"
1790:
3405:
Beausoleil SA, Villén J, Gerber SA, et al. (2006). "A probability-based approach for high-throughput protein phosphorylation analysis and site localization".
1713:. The ~30% of patients in whom the fusion gene effects non-eosinophilic granulocyte or lymphoid cell lineages present with signs and symptoms respectively of
77:
696:
677:
1596:
2711:"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome"
2455:
3314:
2018:
2000:
1862:
While the success of
Gleevec in treating the myeloproliferative neoplasm/myeloblastic leukemia or T-lymphoblastic leukemia/lymphoma forms of
3455:
2454:
Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ (2017).
241:
1786:
1525:
1416:
1396:
1345:
1337:
1813:
fusion gene-induced eosinophil leukemia diseases, unlike most other diseases involving hypereosinophilia, are typically resistant to
1112:
1580:
1494:
involved in hematological malignancies. This suggests that the initial underlying genetic defect in these malignancies can begin in
1119:
3205:
Rual JF, Venkatesan K, Hao T, et al. (2005). "Towards a proteome-scale map of the human protein-protein interaction network".
2990:"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia"
218:
2086:
1911:
1987:
1966:
1528:
that includes its juxtamembrane domain which normally blocks tyrosine kinase activity unless PDGFRA is bound to its activating
1533:
1306:
1983:
1843:
uncommon but has been observed in patients whose mutated cells develop a T674I or D842V mutation in the fused gene. Should
1618:
pathways. The FIP1L1 component of FIP1L1-PDGFRA is required for the fusion protein to activate STAT4 and protein kinase B.
140:
115:
1636:
1561:
3354:"Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent"
2317:"World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management"
1962:
2039:"Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs"
1878:
1848:
1831:
1722:
1702:
1440:
1372:
57:
1937:
as well as more aggressive therapies could not be evaluated because of severity and rapid progression of the diseases;
1856:
1569:
254:
153:
1941:
and in vitro studies indicate that the FIP1L1-RARA fusion protein represses the activation of RARA-activated genes.
1313:
becomes active in phosphorylating proteins that, among other functions, promote cell growth and proliferation. (The
1734:
1710:
1686:
1632:
1557:
247:
146:
1364:
3299:
Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia
2834:"The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia"
1706:
1674:
1298:
1254:
1209:
741:
65:
3078:"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)"
1599:
that promote these functions. For example, in vitro studies show that a FIP1L1-PDGFRA fusion gene stimulates
1762:
1678:
1521:
1495:
1420:
722:
2561:"FIP1L1/RARA with breakpoint at FIP1L1 intron 13: a variant translocation in acute promyelocytic leukemia"
1899:
1774:
1714:
1891:
1754:
1573:
1925:, a ligand for the RARA protein, is exceptionally potent in causing a human eosinophil line to die by
3365:
3214:
3036:
2947:"Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase"
2904:"Human RNPS1 and its associated factors: a versatile alternative pre-mRNA splicing regulator in vivo"
2757:
2669:
1237:
129:
44:
1898:. Translocations between this 17q21.2 locus and several other loci have been associated with acute
1536:. FIP1L1-PDGFRA fusion proteins are also resistant to PDGFRA's normal pathway of degradation, i.e.
1407:). The FIP1 motif of 40 amino acids on FIP1L1 is responsible for its binding to CPSF1. CPSF1 is an
1383:
that also has been implicated in the development of human leukemic diseases in three case reports.
1266:
1095:
1091:
1083:
1079:
1058:
1054:
1050:
1046:
1042:
1038:
1034:
1030:
1026:
1022:
1018:
1014:
1010:
1006:
1002:
998:
994:
990:
986:
982:
978:
974:
970:
966:
962:
958:
954:
950:
946:
942:
938:
934:
930:
926:
922:
918:
914:
910:
906:
902:
892:
888:
880:
876:
856:
852:
844:
840:
815:
811:
2559:
Menezes J, Acquadro F, Perez-Pons de la Villa C, García-Sánchez F, Álvarez S, Cigudosa JC (2011).
3430:
3332:
3238:
2488:
2392:
2346:
2246:
2185:
89:
2658:"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences"
1914:. Relatively little is known about function of or therapy for these translocations except that:
1087:
884:
848:
819:
492:
3422:
3393:
3320:
3310:
3281:
3230:
3193:
3150:
3107:
3064:
3011:
2976:
2933:
2890:
2855:
2820:
2785:
2732:
2697:
2644:
2590:
2523:
2480:
2433:
2384:
2338:
2294:
2238:
2177:
2104:"FIP1L1 factor interacting with PAPOLA and CPSF1 [Homo sapiens (human)] - Gene - NCBI"
2068:
1553:
1444:
37:
3414:
3383:
3373:
3302:
3271:
3263:
3222:
3183:
3175:
3140:
3132:
3097:
3089:
3054:
3044:
3001:
2966:
2958:
2923:
2915:
2880:
2845:
2810:
2775:
2765:
2722:
2687:
2677:
2634:
2626:
2580:
2572:
2515:
2470:
2423:
2376:
2328:
2284:
2228:
2220:
2167:
2058:
2050:
1690:
1612:
334:
265:
209:
164:
85:
1918:
the fusion gene was generated juxtaposing exons 15 and 3 of FIP1L1 and RARA, respectively;
1785:
fusion gene in the blood and/or bone marrow cells of sufferers by cytogenic analysis using
1781:-induced disease. Rather, definitive results are obtained by detecting the presence of the
1603:
to proliferate and differentiate along the eosinophil lineage by causing the activation of
3344:
1770:
1761:-induced diseases because of the very different treatments for the two types of diseases.
1592:
1588:
1517:
1310:
309:
3369:
3218:
3040:
2761:
2673:
1910:
gene loci are associated with two cases of acute promyelocytic leukemia and one case of
1866:
fusion gene-induced disease is unclear, initial treatment with the drug is recommended.
3388:
3353:
3276:
3251:
3188:
3163:
2971:
2946:
2746:"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome"
2585:
2560:
2367:
Helbig G (February 2018). "Imatinib for the treatment of hypereosinophilic syndromes".
1814:
1615:
1400:
1241:
3145:
3120:
3102:
3077:
3059:
3024:
2928:
2903:
2780:
2745:
2692:
2657:
2639:
2614:
2156:"Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1"
2063:
2038:
611:
606:
601:
596:
591:
586:
581:
565:
560:
555:
539:
534:
3449:
1934:
1922:
1682:
1491:
1487:
1302:
521:
3434:
3297:
Fusion in
Idiopathic Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia".
3179:
2919:
2492:
2350:
2250:
2189:
1757:, a disease which may also present with eosinophilia and must be distinguished from
69:
3242:
2396:
1887:
1852:
1694:
1549:
327:
106:
2380:
2576:
2289:
2272:
1847:
fusion gene-induced eosinophil leukemia diseases become resistant to or enter an
1733:
Patients expressing the eosinophil-driving fusion protein typically present with
1415:-rich sequences in pre-mRNA, concurrently binds with and stimulates POPOLA, i.e.
93:
3306:
2542:"RARA retinoic acid receptor alpha [Homo sapiens (human)] - Gene - NCBI"
2023:
National Center for
Biotechnology Information, U.S. National Library of Medicine
2005:
National Center for
Biotechnology Information, U.S. National Library of Medicine
1739:
1698:
1475:
1471:
1428:
1333:
1259:
1205:
3006:
2989:
2850:
2833:
2815:
2798:
2428:
2411:
2121:
410:
2519:
2224:
1895:
1766:
1537:
1500:
1479:
1233:
226:
123:
73:
2962:
2172:
2155:
2122:"Pre-mRNA 3'-end-processing factor FIP1 (Q6UN15) < InterPro < EMBL-EBI"
1830:-approved and most successful treatment for Philadelphia chromosome-positive
1445:
diseases associated with pathologically increased levels of blood eosinophils
1352:
at variable breakpoints in both genes extending over a 40 kilobase region in
3378:
3049:
2869:"Complete sequencing and characterization of 21,243 full-length human cDNAs"
2770:
1926:
1883:
1541:
1483:
1270:
641:
470:
348:
293:
280:
192:
179:
81:
3426:
3397:
3324:
3285:
3234:
3197:
3154:
3111:
3068:
3015:
2980:
2937:
2894:
2859:
2824:
2789:
2736:
2701:
2682:
2648:
2594:
2527:
2484:
2437:
2388:
2342:
2298:
2242:
2181:
2072:
2103:
1524:, i.e. continuously active: the fusion proteins lack the intact protein's
1200:(also known as Rhe, FIP1, and hFip1). A medically important aspect of the
1159:
1154:
3267:
2727:
2710:
2541:
1835:
1823:
1746:
1718:
1670:
1604:
1505:
1448:
1326:
1322:
1318:
1278:
1244:
results in multiple transcript variants encoding distinct FIP1L1 protein
1213:
1143:
786:
767:
3226:
2410:
Séguéla PE, Iriart X, Acar P, Montaudon M, Roudaut R, Thambo JB (2015).
3136:
3093:
2412:"Eosinophilic cardiac disease: Molecular, clinical and imaging aspects"
2054:
1902:. Three case reports have found that chromosome translocations between
1245:
1190:
753:
708:
2630:
2475:
2333:
2316:
2233:
1252:
gene is found in a wide range of species, being designated as FIP1 in
1666:
1529:
1432:
1412:
1286:
1173:
1127:
663:
3418:
2154:
Vega F, Medeiros LJ, Bueso-Ramos CE, Arboleda P, Miranda RN (2015).
1228:
gene is located on chromosome 4 at position q12 (4q12), contains 19
3025:"Large-scale characterization of HeLa cell nuclear phosphoproteins"
2885:
2868:
1701:
that from in the heart); pulmonary airway and parenchymal disease;
1379:, (17q12) at various points yields a (15;17)(q22;q21) fusion gene,
1608:
1392:
1229:
1177:
626:
622:
2506:
2456:"Guideline for the investigation and management of eosinophilia"
1600:
1404:
1277:
gene (i.e.cysteine rich hydrophobic domain 2 gene) to create an
1197:
501:
61:
3023:
Beausoleil SA, Jedrychowski M, Schwartz D, et al. (2004).
1297:, platelet-derived growth factor receptor alpha (PDGFRA), is a
2988:
Pardanani A, Brockman SR, Paternoster SF, et al. (2004).
1827:
1408:
2797:
Pardanani A, Ketterling RP, Brockman SR, et al. (2004).
1817:
therapy. However, and unlike most cases of myeloid leukemia,
1643:(Version 3) is ~0.036 per 100,000 with the mean frequency of
566:
mRNA cleavage and polyadenylation specificity factor complex
48:, FIP1, Rhe, hFip1, factor interacting with PAPOLA and CPSF1
3293:
Cools J, Stover EH, Gilliland DG (2006). "Detection of the
2656:
Strausberg RL, Feingold EA, Grouse LH, et al. (2003).
3121:"From ORFeome to biology: a functional genomics pipeline"
1393:
cleavage and polyadenylation specificity factor subunit 1
2615:"DNA cloning using in vitro site-specific recombination"
317:
3250:
Mehrle A, Rosenfelder H, Schupp I, et al. (2006).
3076:
Gerhard DS, Wagner L, Feingold EA, et al. (2004).
2945:
Kaufmann I, Martin G, Friedlein A, et al. (2005).
2902:
Sakashita E, Tatsumi S, Werner D, et al. (2004).
2832:
Cools J, Quentmeier H, Huntly BJ, et al. (2004).
1838:. More recently, the FDA approved Gleevec for treating
1520:
activity but, unlike PDGFRA, their tyrosine kinase is
1262:
as well as mice and numerous other mammalian species.
1641:
1232:, and codes for a complete protein consisting of 594
482:
2744:
Griffin JH, Leung J, Bruner RJ, et al. (2003).
2709:
Cools J, DeAngelo DJ, Gotlib J, et al. (2003).
1516:
FIP1L1-PDGFRA fusion proteins retain PDGFRA-related
1287:
platelet-derived growth factor receptor alpha gene (
1859:used to treat aggressive leukemia may be required.
1072:
875:
833:
804:
2867:Ota T, Suzuki Y, Nishikawa T, et al. (2004).
1979:
1977:
1975:
1958:
1956:
1954:
3352:Stover EH, Chen J, Folens C, et al. (2006).
2087:"Entrez Gene: FIP1L1 FIP1 like 1 (S. cerevisiae)"
1769:but usually does not contain elevated numbers of
264:
163:
3119:Wiemann S, Arlt D, Huber W, et al. (2004).
1777:but does not give definitive results indicating
1433:platelet-derived growth factor receptor, alpha (
2508:Immunology and Allergy Clinics of North America
2449:
2447:
2362:
2360:
2310:
2308:
2266:
2264:
2262:
2260:
2205:
2203:
2201:
2199:
1826:. This drug, also known as Gleevec, has been a
1791:reverse transcription polymerase chain reaction
2149:
2147:
2145:
2143:
2141:
2139:
2137:
2135:
1984:GRCm38: Ensembl release 89: ENSMUSG00000029227
612:pre-mRNA cleavage required for polyadenylation
587:termination of RNA polymerase II transcription
3162:Zhao X, Oberg D, Rush M, et al. (2005).
8:
1894:which in turn regulate the transcription of
1738:exhibit elevations in their serum levels of
1204:gene is its fusion with other genes to form
1963:GRCh38: Ensembl release 89: ENSG00000145216
1719:lymphoma T-lymphoblastic leukemia/lymphoma
1677:(i.e. heart disease which may manifest as
872:
637:
517:
305:
204:
101:
3387:
3377:
3275:
3187:
3144:
3101:
3058:
3048:
3005:
2970:
2927:
2884:
2849:
2814:
2779:
2769:
2726:
2691:
2681:
2638:
2613:Hartley JL, Temple GF, Brasch MA (2001).
2584:
2474:
2427:
2332:
2288:
2232:
2171:
2098:
2096:
2062:
1851:while on Gleevec therapy, the aggressive
1443:(RARA) genes are causes of certain human
1765:may reveal increases in eosinophils and
1395:(CPSF1) complex that polyadenylates the
1317:mutation was the first description of a
1950:
1470:fusion genes have been detected in the
1265:In humans, an interstitial chromosomal
3340:
3330:
2160:American Journal of Clinical Pathology
1576:not distinguished by eosinophilia; or
1187:Pre-mRNA 3'-end-processing factor FIP1
18:
2273:"Myeloid neoplasms with eosinophilia"
1693:, or blockage of arteries due to the
269:
230:
225:
168:
127:
122:
7:
2369:Expert Review of Clinical Immunology
1496:myeloid or lymphoid progenitor cells
2416:Archives of Cardiovascular Diseases
1793:testing. Non-eosinophilic forms of
1753:and tryptase are seen regularly in
1305:. When bound by its proper ligand,
3301:. Vol. 125. pp. 177–87.
1787:fluorescence in situ hybridization
1417:polynucleotide adenylyltransferase
1069:
830:
801:
777:
758:
732:
713:
687:
668:
487:
405:
343:
322:
14:
1581:T-lymphoblastic leukemia/lymphoma
1411:processing protein that binds to
1356:and a small region of exon 12 in
1193:that in humans is encoded by the
1912:juvenile myelomonocytic leukemia
1587:-induced disease presented as a
491:
253:
246:
240:
217:
152:
145:
139:
114:
3180:10.1128/JVI.79.7.4270-4288.2005
2920:10.1128/MCB.24.3.1174-1187.2004
1749:. Elevations of serum vitamin B
1685:due to injured cardiac muscle,
1595:and thereby activating certain
2463:British Journal of Haematology
2321:American Journal of Hematology
1711:organs targeted by eosinophils
1656:The ~70% of patients with the
1631:The age-adjusted incidence of
1534:platelet-derived growth factor
1307:platelet-derived growth factor
582:mRNA splicing, via spliceosome
502:More reference expression data
471:More reference expression data
1:
3252:"The LIFEdb database in 2006"
2381:10.1080/1744666X.2018.1425142
1798:require demonstration of the
1660:fusion gene (also termed the
1637:chronic eosinophilic leukemia
1562:chronic eosinophilic leukemia
238:
137:
16:Protein-coding gene in humans
3358:Proc. Natl. Acad. Sci. U.S.A
3029:Proc. Natl. Acad. Sci. U.S.A
2750:Proc. Natl. Acad. Sci. U.S.A
2662:Proc. Natl. Acad. Sci. U.S.A
2577:10.3324/haematol.2011.047134
2290:10.1182/blood-2016-10-695973
1879:Retinoic acid receptor alpha
1832:chronic myelogenous leukemia
1802:fusion genes for diagnosis.
1703:eosinophilic gastroenteritis
1441:retinoic acid receptor alpha
1373:retinoic acid receptor alpha
3456:Genes on human chromosome 4
2271:Reiter A, Gotlib J (2017).
1890:, and the transcription of
1857:bone marrow transplantation
1709:; and dysfunction of other
1570:myeloproliferative neoplasm
1419:, and then proceeds to add
1391:FIP1L1 is a subunit of the
1321:mutation resulting from an
3472:
3262:(Database issue): D415–8.
3007:10.1182/blood-2004-03-0787
2851:10.1182/blood-2003-07-2479
2816:10.1182/blood-2003-05-1627
2429:10.1016/j.acvd.2015.01.006
1849:accelerated or blast phase
1687:restrictive cardiomyopathy
1633:hypereosinophilic syndrome
1558:hypereosinophilic syndrome
1431:between it and either the
3307:10.1385/1-59745-017-0:177
2520:10.1016/j.iac.2015.05.006
2225:10.1007/s00277-014-2085-1
2019:"Mouse PubMed Reference:"
2001:"Human PubMed Reference:"
1933:the disease responses to
1365:chromosomal translocation
1327:chromosomal translocation
1158:
1153:
1149:
1142:
1126:
1107:
1076:
899:
868:
837:
808:
797:
784:
780:
765:
761:
752:
739:
735:
720:
716:
707:
694:
690:
675:
671:
662:
647:
640:
636:
620:
520:
516:
499:
490:
481:
468:
417:
408:
355:
346:
316:
308:
304:
287:
274:
237:
216:
207:
203:
186:
173:
136:
113:
104:
100:
55:
52:
42:
35:
30:
26:
21:
2963:10.1038/sj.emboj.7600070
2173:10.1309/AJCPMORR5Z2IKCEM
1834:(CML) and certain other
1707:eosinophilic esophagitis
1675:eosinophilic myocarditis
1299:tyrosine kinase receptor
1255:Saccharomyces cerevisiae
1210:clonal hypereosinophilia
1172:Factor interacting with
602:mRNA export from nucleus
395:internal globus pallidus
359:tendon of biceps brachii
3379:10.1073/pnas.0601192103
3050:10.1073/pnas.0404720101
2771:10.1073/pnas.0932698100
1763:Bone marrow examination
1679:coronary artery disease
1583:. At least one case of
1113:Chr 4: 53.38 – 53.46 Mb
2683:10.1073/pnas.242603899
1900:promyelocytic leukemia
1775:acute myeloid leukemia
1715:acute myeloid leukemia
1552:which may progress to
1258:(yeast) and fip1l1 in
1120:Chr 5: 74.7 – 74.76 Mb
597:mRNA 3'-end processing
1892:transcription factors
1755:systemic mastocytosis
1574:myeloblastic leukemia
1323:interstitial deletion
1293:gene. The product of
2728:10.1056/NEJMoa025217
2546:www.ncbi.nlm.nih.gov
2213:Annals of Hematology
2108:www.ncbi.nlm.nih.gov
1723:lymphocytic leukemia
1273:at 4q12 deletes the
1238:alternative splicing
1216:diseases in humans.
607:mRNA polyadenylation
232:Chromosome 5 (mouse)
130:Chromosome 4 (human)
3370:2006PNAS..103.8078S
3227:10.1038/nature04209
3219:2005Natur.437.1173R
3041:2004PNAS..10112130B
2762:2003PNAS..100.7830G
2674:2002PNAS...9916899M
391:ganglionic eminence
3268:10.1093/nar/gkj139
3137:10.1101/gr.2576704
3094:10.1101/gr.2596504
2055:10.1101/gr.GR1547R
742:ENSMUSG00000029227
575:Biological process
549:Cellular component
528:Molecular function
453:supraoptic nucleus
94:FIP1L1 - orthologs
3316:978-1-59745-017-1
3256:Nucleic Acids Res
2668:(26): 16899–903.
2631:10.1101/gr.143000
2476:10.1111/bjh.14488
2334:10.1002/ajh.24196
2315:Gotlib J (2015).
1882:differentiation,
1735:hypereosinophilia
1554:hypereosinophilia
1169:
1168:
1165:
1164:
1138:
1137:
1103:
1102:
1066:
1065:
864:
863:
827:
826:
793:
792:
774:
773:
748:
747:
729:
728:
703:
702:
684:
683:
632:
631:
512:
511:
508:
507:
477:
476:
464:
463:
402:
401:
300:
299:
199:
198:
3463:
3438:
3401:
3391:
3381:
3348:
3342:
3338:
3336:
3328:
3289:
3279:
3246:
3213:(7062): 1173–8.
3201:
3191:
3158:
3148:
3131:(10B): 2136–44.
3115:
3105:
3072:
3062:
3052:
3019:
3009:
2984:
2974:
2941:
2931:
2898:
2888:
2863:
2853:
2828:
2818:
2793:
2783:
2773:
2740:
2730:
2705:
2695:
2685:
2652:
2642:
2599:
2598:
2588:
2556:
2550:
2549:
2538:
2532:
2531:
2503:
2497:
2496:
2478:
2460:
2451:
2442:
2441:
2431:
2407:
2401:
2400:
2364:
2355:
2354:
2336:
2312:
2303:
2302:
2292:
2268:
2255:
2254:
2236:
2207:
2194:
2193:
2175:
2151:
2130:
2129:
2118:
2112:
2111:
2100:
2091:
2090:
2083:
2077:
2076:
2066:
2033:
2027:
2026:
2015:
2009:
2008:
1997:
1991:
1981:
1970:
1960:
1691:cardiac fibrosis
1639:reported by the
1622:Clinical aspects
1613:protein kinase B
1504:cells along the
1403:(pre-mRNA) (see
1371:(4q12) with the
1336:consists of the
1319:gain of function
1151:
1150:
1122:
1115:
1098:
1070:
1061:
873:
869:RefSeq (protein)
859:
831:
822:
802:
778:
759:
733:
714:
688:
669:
638:
518:
504:
495:
488:
473:
441:genital tubercle
433:secondary oocyte
413:
411:Top expressed in
406:
383:ventricular zone
351:
349:Top expressed in
344:
323:
306:
296:
283:
272:
257:
250:
244:
233:
221:
205:
195:
182:
171:
156:
149:
143:
132:
118:
102:
96:
47:
40:
19:
3471:
3470:
3466:
3465:
3464:
3462:
3461:
3460:
3446:
3445:
3443:
3441:
3419:10.1038/nbt1240
3413:(10): 1285–92.
3407:Nat. Biotechnol
3404:
3364:(21): 8078–83.
3351:
3339:
3329:
3317:
3292:
3249:
3204:
3161:
3118:
3088:(10B): 2121–7.
3075:
3035:(33): 12130–5.
3022:
3000:(10): 3038–45.
2987:
2944:
2908:Mol. Cell. Biol
2901:
2866:
2831:
2796:
2743:
2721:(13): 1201–14.
2715:N. Engl. J. Med
2708:
2655:
2625:(11): 1788–95.
2612:
2608:
2606:Further reading
2603:
2602:
2558:
2557:
2553:
2540:
2539:
2535:
2505:
2504:
2500:
2458:
2453:
2452:
2445:
2409:
2408:
2404:
2366:
2365:
2358:
2327:(11): 1077–89.
2314:
2313:
2306:
2270:
2269:
2258:
2209:
2208:
2197:
2153:
2152:
2133:
2120:
2119:
2115:
2102:
2101:
2094:
2085:
2084:
2080:
2035:
2034:
2030:
2017:
2016:
2012:
1999:
1998:
1994:
1982:
1973:
1961:
1952:
1947:
1872:
1808:
1771:precursor cells
1752:
1743:
1731:
1654:
1629:
1624:
1593:phosphorylating
1589:myeloid sarcoma
1518:Tyrosine kinase
1514:
1465:
1460:
1401:precursor mRNAs
1389:
1311:tyrosine kinase
1222:
1160:View/Edit Mouse
1155:View/Edit Human
1118:
1111:
1108:Location (UCSC)
1094:
1090:
1086:
1082:
1078:
1057:
1053:
1049:
1045:
1041:
1037:
1033:
1029:
1025:
1021:
1017:
1013:
1009:
1005:
1001:
997:
993:
989:
985:
981:
977:
973:
969:
965:
961:
957:
953:
949:
945:
941:
937:
933:
929:
925:
921:
917:
913:
909:
905:
901:
895:
891:
887:
883:
879:
855:
851:
847:
843:
839:
818:
814:
810:
723:ENSG00000145216
616:
592:mRNA processing
570:
544:
535:protein binding
500:
469:
460:
455:
451:
447:
443:
439:
435:
431:
427:
423:
409:
398:
393:
389:
385:
381:
377:
373:
369:
365:
363:Achilles tendon
361:
347:
291:
278:
270:
260:
259:
258:
251:
231:
208:Gene location (
190:
177:
169:
159:
158:
157:
150:
128:
105:Gene location (
56:
43:
36:
17:
12:
11:
5:
3469:
3467:
3459:
3458:
3448:
3447:
3440:
3439:
3402:
3349:
3341:|journal=
3315:
3290:
3247:
3202:
3174:(7): 4270–88.
3159:
3116:
3073:
3020:
2985:
2942:
2914:(3): 1174–87.
2899:
2886:10.1038/ng1285
2864:
2829:
2794:
2756:(13): 7830–5.
2741:
2706:
2653:
2609:
2607:
2604:
2601:
2600:
2571:(10): 1565–6.
2551:
2533:
2498:
2469:(4): 553–572.
2443:
2402:
2375:(2): 163–170.
2356:
2304:
2283:(6): 704–714.
2256:
2219:(9): 1473–81.
2195:
2131:
2113:
2092:
2078:
2028:
2010:
1992:
1971:
1949:
1948:
1946:
1943:
1871:
1868:
1815:corticosteroid
1807:
1804:
1750:
1741:
1730:
1727:
1653:
1650:
1628:
1625:
1623:
1620:
1616:cell signaling
1513:
1510:
1464:
1461:
1459:
1453:
1388:
1387:FIPL1 function
1385:
1344:united to the
1285:gene with the
1281:fusion of the
1242:precursor mRNA
1221:
1218:
1185:; also termed
1167:
1166:
1163:
1162:
1157:
1147:
1146:
1140:
1139:
1136:
1135:
1133:
1131:
1124:
1123:
1116:
1109:
1105:
1104:
1101:
1100:
1074:
1073:
1067:
1064:
1063:
897:
896:
870:
866:
865:
862:
861:
835:
834:
828:
825:
824:
806:
805:
799:
795:
794:
791:
790:
782:
781:
775:
772:
771:
763:
762:
756:
750:
749:
746:
745:
737:
736:
730:
727:
726:
718:
717:
711:
705:
704:
701:
700:
692:
691:
685:
682:
681:
673:
672:
666:
660:
659:
654:
649:
645:
644:
634:
633:
630:
629:
618:
617:
615:
614:
609:
604:
599:
594:
589:
584:
578:
576:
572:
571:
569:
568:
563:
558:
552:
550:
546:
545:
543:
542:
537:
531:
529:
525:
524:
514:
513:
510:
509:
506:
505:
497:
496:
485:
479:
478:
475:
474:
466:
465:
462:
461:
459:
458:
454:
450:
446:
442:
438:
434:
430:
429:tail of embryo
426:
422:
421:primary oocyte
418:
415:
414:
403:
400:
399:
397:
396:
392:
388:
384:
380:
376:
372:
368:
364:
360:
356:
353:
352:
340:
339:
331:
320:
314:
313:
310:RNA expression
302:
301:
298:
297:
289:
285:
284:
276:
273:
268:
262:
261:
252:
245:
239:
235:
234:
229:
223:
222:
214:
213:
201:
200:
197:
196:
188:
184:
183:
175:
172:
167:
161:
160:
151:
144:
138:
134:
133:
126:
120:
119:
111:
110:
98:
97:
54:
50:
49:
41:
33:
32:
28:
27:
24:
23:
15:
13:
10:
9:
6:
4:
3:
2:
3468:
3457:
3454:
3453:
3451:
3444:
3436:
3432:
3428:
3424:
3420:
3416:
3412:
3408:
3403:
3399:
3395:
3390:
3385:
3380:
3375:
3371:
3367:
3363:
3359:
3355:
3350:
3346:
3334:
3326:
3322:
3318:
3312:
3308:
3304:
3300:
3296:
3295:FIP1L1-PDGFRA
3291:
3287:
3283:
3278:
3273:
3269:
3265:
3261:
3257:
3253:
3248:
3244:
3240:
3236:
3232:
3228:
3224:
3220:
3216:
3212:
3208:
3203:
3199:
3195:
3190:
3185:
3181:
3177:
3173:
3169:
3165:
3160:
3156:
3152:
3147:
3142:
3138:
3134:
3130:
3126:
3122:
3117:
3113:
3109:
3104:
3099:
3095:
3091:
3087:
3083:
3079:
3074:
3070:
3066:
3061:
3056:
3051:
3046:
3042:
3038:
3034:
3030:
3026:
3021:
3017:
3013:
3008:
3003:
2999:
2995:
2991:
2986:
2982:
2978:
2973:
2968:
2964:
2960:
2957:(3): 616–26.
2956:
2952:
2948:
2943:
2939:
2935:
2930:
2925:
2921:
2917:
2913:
2909:
2905:
2900:
2896:
2892:
2887:
2882:
2878:
2874:
2870:
2865:
2861:
2857:
2852:
2847:
2844:(7): 2802–5.
2843:
2839:
2835:
2830:
2826:
2822:
2817:
2812:
2809:(9): 3093–6.
2808:
2804:
2800:
2795:
2791:
2787:
2782:
2777:
2772:
2767:
2763:
2759:
2755:
2751:
2747:
2742:
2738:
2734:
2729:
2724:
2720:
2716:
2712:
2707:
2703:
2699:
2694:
2689:
2684:
2679:
2675:
2671:
2667:
2663:
2659:
2654:
2650:
2646:
2641:
2636:
2632:
2628:
2624:
2620:
2616:
2611:
2610:
2605:
2596:
2592:
2587:
2582:
2578:
2574:
2570:
2566:
2565:Haematologica
2562:
2555:
2552:
2547:
2543:
2537:
2534:
2529:
2525:
2521:
2517:
2514:(3): 561–75.
2513:
2509:
2502:
2499:
2494:
2490:
2486:
2482:
2477:
2472:
2468:
2464:
2457:
2450:
2448:
2444:
2439:
2435:
2430:
2425:
2422:(4): 258–68.
2421:
2417:
2413:
2406:
2403:
2398:
2394:
2390:
2386:
2382:
2378:
2374:
2370:
2363:
2361:
2357:
2352:
2348:
2344:
2340:
2335:
2330:
2326:
2322:
2318:
2311:
2309:
2305:
2300:
2296:
2291:
2286:
2282:
2278:
2274:
2267:
2265:
2263:
2261:
2257:
2252:
2248:
2244:
2240:
2235:
2230:
2226:
2222:
2218:
2214:
2206:
2204:
2202:
2200:
2196:
2191:
2187:
2183:
2179:
2174:
2169:
2166:(3): 377–92.
2165:
2161:
2157:
2150:
2148:
2146:
2144:
2142:
2140:
2138:
2136:
2132:
2127:
2126:www.ebi.ac.uk
2123:
2117:
2114:
2109:
2105:
2099:
2097:
2093:
2088:
2082:
2079:
2074:
2070:
2065:
2060:
2056:
2052:
2049:(3): 422–35.
2048:
2044:
2040:
2032:
2029:
2024:
2020:
2014:
2011:
2006:
2002:
1996:
1993:
1989:
1985:
1980:
1978:
1976:
1972:
1968:
1964:
1959:
1957:
1955:
1951:
1944:
1942:
1940:
1936:
1935:retinoic acid
1932:
1928:
1924:
1923:retinoic acid
1921:
1917:
1913:
1909:
1905:
1901:
1897:
1893:
1889:
1885:
1880:
1876:
1869:
1867:
1865:
1864:FIP1L1-PDGFRA
1860:
1858:
1854:
1850:
1846:
1845:FIP1L1-PDGFRA
1841:
1840:FIP1L1-PDGFRA
1837:
1833:
1829:
1825:
1820:
1819:FIP1L1-PDGFRA
1816:
1812:
1811:FIP1L1-PDGFRA
1805:
1803:
1801:
1800:FIP1L1-PDGFRA
1796:
1795:FIP1L1-PDGFRA
1792:
1788:
1784:
1783:FIP1L1-PDGFRA
1780:
1779:FIP1L1-PDGFRA
1776:
1772:
1768:
1764:
1760:
1759:FIP1L1-PDGFRA
1756:
1748:
1744:
1736:
1728:
1726:
1724:
1720:
1716:
1712:
1708:
1704:
1700:
1696:
1692:
1688:
1684:
1683:heart failure
1680:
1676:
1672:
1668:
1663:
1659:
1658:FIP1L1-PDGFRA
1651:
1649:
1646:
1645:FIP1L1-PDGFRA
1642:
1638:
1634:
1626:
1621:
1619:
1617:
1614:
1610:
1606:
1602:
1598:
1594:
1590:
1586:
1585:FIP1L1-PDGFRA
1582:
1579:
1575:
1571:
1567:
1563:
1559:
1555:
1551:
1547:
1543:
1542:ubiquitnation
1539:
1535:
1531:
1527:
1523:
1519:
1511:
1509:
1507:
1502:
1497:
1493:
1492:B lymphocytes
1489:
1488:T lymphocytes
1485:
1481:
1477:
1473:
1469:
1468:FIP1L1-PDGFRA
1462:
1457:
1456:FIP1L1-PDGFRA
1454:
1452:
1450:
1446:
1442:
1438:
1436:
1430:
1427:
1422:
1418:
1414:
1410:
1406:
1402:
1398:
1394:
1386:
1384:
1382:
1378:
1374:
1370:
1366:
1361:
1359:
1355:
1351:
1347:
1343:
1339:
1335:
1332:
1331:FIP1L1-PDGFRA
1328:
1325:instead of a
1324:
1320:
1316:
1315:FIP1L1-PDGFRA
1312:
1308:
1304:
1303:RTK class III
1300:
1296:
1292:
1290:
1284:
1280:
1276:
1272:
1269:of about 800
1268:
1263:
1261:
1257:
1256:
1251:
1247:
1243:
1239:
1235:
1231:
1227:
1219:
1217:
1215:
1211:
1207:
1203:
1199:
1196:
1192:
1188:
1184:
1180:
1179:
1175:
1161:
1156:
1152:
1148:
1145:
1141:
1134:
1132:
1129:
1125:
1121:
1117:
1114:
1110:
1106:
1099:
1097:
1093:
1089:
1085:
1081:
1075:
1071:
1068:
1062:
1060:
1056:
1052:
1048:
1044:
1040:
1036:
1032:
1028:
1024:
1020:
1016:
1012:
1008:
1004:
1000:
996:
992:
988:
984:
980:
976:
972:
968:
964:
960:
956:
952:
948:
944:
940:
936:
932:
928:
924:
920:
916:
912:
908:
904:
898:
894:
890:
886:
882:
878:
874:
871:
867:
860:
858:
854:
850:
846:
842:
836:
832:
829:
823:
821:
817:
813:
807:
803:
800:
798:RefSeq (mRNA)
796:
789:
788:
783:
779:
776:
770:
769:
764:
760:
757:
755:
751:
744:
743:
738:
734:
731:
725:
724:
719:
715:
712:
710:
706:
699:
698:
693:
689:
686:
680:
679:
674:
670:
667:
665:
661:
658:
655:
653:
650:
646:
643:
639:
635:
628:
624:
619:
613:
610:
608:
605:
603:
600:
598:
595:
593:
590:
588:
585:
583:
580:
579:
577:
574:
573:
567:
564:
562:
559:
557:
554:
553:
551:
548:
547:
541:
538:
536:
533:
532:
530:
527:
526:
523:
522:Gene ontology
519:
515:
503:
498:
494:
489:
486:
484:
480:
472:
467:
456:
452:
448:
444:
440:
436:
432:
428:
424:
420:
419:
416:
412:
407:
404:
394:
390:
386:
382:
378:
374:
370:
366:
362:
358:
357:
354:
350:
345:
342:
341:
338:
336:
332:
330:
329:
325:
324:
321:
319:
315:
311:
307:
303:
295:
290:
286:
282:
277:
271:5|5 C3.3
267:
263:
256:
249:
243:
236:
228:
224:
220:
215:
211:
206:
202:
194:
189:
185:
181:
176:
166:
162:
155:
148:
142:
135:
131:
125:
121:
117:
112:
108:
103:
99:
95:
91:
87:
83:
79:
75:
71:
67:
63:
59:
51:
46:
39:
34:
29:
25:
20:
3442:
3410:
3406:
3361:
3357:
3298:
3294:
3259:
3255:
3210:
3206:
3171:
3167:
3128:
3124:
3085:
3081:
3032:
3028:
2997:
2993:
2954:
2950:
2911:
2907:
2876:
2872:
2841:
2837:
2806:
2802:
2753:
2749:
2718:
2714:
2665:
2661:
2622:
2618:
2568:
2564:
2554:
2545:
2536:
2511:
2507:
2501:
2466:
2462:
2419:
2415:
2405:
2372:
2368:
2324:
2320:
2280:
2276:
2216:
2212:
2163:
2159:
2125:
2116:
2107:
2081:
2046:
2042:
2031:
2022:
2013:
2004:
1995:
1938:
1930:
1919:
1915:
1907:
1903:
1888:myelopoiesis
1874:
1873:
1863:
1861:
1853:chemotherapy
1844:
1839:
1818:
1810:
1809:
1799:
1794:
1782:
1778:
1758:
1732:
1695:embolization
1661:
1657:
1655:
1652:Presentation
1644:
1630:
1584:
1577:
1565:
1550:eosinophilia
1545:
1522:constitutive
1515:
1467:
1466:
1458:fusion genes
1455:
1434:
1429:gene fusions
1425:
1390:
1380:
1376:
1368:
1362:
1357:
1353:
1349:
1341:
1330:
1314:
1294:
1288:
1282:
1274:
1264:
1253:
1249:
1225:
1223:
1208:which cause
1206:fusion genes
1201:
1194:
1186:
1182:
1171:
1170:
1096:NP_001363894
1092:NP_001363893
1084:NP_001153046
1080:NP_001153045
1077:
1059:NP_001363715
1055:NP_001363714
1051:NP_001363713
1047:NP_001363712
1043:NP_001363711
1039:NP_001363710
1035:NP_001363709
1031:NP_001363708
1027:NP_001363707
1023:NP_001363706
1019:NP_001363705
1015:NP_001363704
1011:NP_001363703
1007:NP_001363702
1003:NP_001363701
999:NP_001363700
995:NP_001363699
991:NP_001363698
987:NP_001363697
983:NP_001363696
979:NP_001363695
975:NP_001363694
971:NP_001363693
967:NP_001363691
963:NP_001363690
959:NP_001363689
955:NP_001363688
951:NP_001363687
947:NP_001363686
943:NP_001363685
939:NP_001363684
935:NP_001363683
931:NP_001363682
927:NP_001363681
923:NP_001363680
919:NP_001363679
915:NP_001363678
911:NP_001363677
907:NP_001363676
903:NP_001363675
900:
893:NP_001363674
889:NP_001363673
881:NP_001128410
877:NP_001128409
857:NM_001376965
853:NM_001376964
845:NM_001159574
841:NM_001159573
838:
816:NM_001134938
812:NM_001134937
809:
785:
766:
740:
721:
695:
676:
656:
651:
457:otic placode
449:otic vesicle
445:aortic valve
379:right testis
333:
326:
53:External IDs
2879:(1): 40–5.
1896:clock genes
1870:FIP1L1-RARA
1699:blood clots
1601:CD34+ cells
1540:-dependent
1476:neutrophils
1472:eosinophils
1381:FIP1L1-RARA
1375:gene, i.e.
1334:fusion gene
1309:(PDGF), it
1260:coho salmon
1236:. However,
1234:amino acids
561:nucleoplasm
540:RNA binding
375:sural nerve
371:left testis
292:74,759,461
279:74,696,110
191:53,460,862
178:53,377,641
31:Identifiers
3125:Genome Res
3082:Genome Res
2873:Nat. Genet
2619:Genome Res
2234:2115/59854
2043:Genome Res
1990:, May 2017
1969:, May 2017
1945:References
1789:or nested
1767:mast cells
1648:children.
1568:a type of
1538:Proteasome
1501:eosinophil
1480:mast cells
1463:Expression
1224:The human
387:left ovary
337:(ortholog)
74:HomoloGene
3343:ignored (
3333:cite book
1927:apoptosis
1884:apoptosis
1806:Treatment
1740:vitamin B
1729:Diagnosis
1627:Incidence
1508:lineage.
1484:monocytes
1449:leukemias
1271:kilobases
1088:NP_077145
885:NP_112179
849:NM_024183
820:NM_030917
642:Orthologs
82:GeneCards
3450:Category
3435:14294292
3427:16964243
3398:16690743
3325:16502585
3286:16381901
3235:16189514
3198:15767428
3168:J. Virol
3155:15489336
3112:15489334
3069:15302935
3016:15284118
2981:14749727
2938:14729963
2895:14702039
2860:14630792
2825:12842979
2790:12808148
2737:12660384
2702:12477932
2649:11076863
2595:21750086
2528:26209900
2493:46856647
2485:28112388
2438:25858537
2389:29303368
2351:42668440
2343:26486351
2299:28028030
2251:25915058
2243:24763514
2190:10435391
2182:26276769
2073:11230166
1986:–
1965:–
1836:diseases
1824:Imatinib
1747:tryptase
1671:erythema
1597:proteins
1548:chronic
1512:Function
1506:lymphoid
1421:adenylyl
1279:in-frame
1267:deletion
1246:isoforms
1214:leukemic
1144:Wikidata
621:Sources:
3389:1472432
3366:Bibcode
3277:1347501
3243:4427026
3215:Bibcode
3189:1061554
3037:Bibcode
2972:1271804
2758:Bibcode
2670:Bibcode
2586:3186322
2397:6580949
1988:Ensembl
1967:Ensembl
1855:and/or
1689:due to
1447:and/or
1329:.) The
1301:of the
1240:of its
1191:protein
1189:) is a
754:UniProt
709:Ensembl
648:Species
627:QuickGO
556:nucleus
425:saccule
312:pattern
70:1914149
38:Aliases
3433:
3425:
3396:
3386:
3323:
3313:
3284:
3274:
3241:
3233:
3207:Nature
3196:
3186:
3153:
3146:528930
3143:
3110:
3103:528928
3100:
3067:
3060:514446
3057:
3014:
2979:
2969:
2951:EMBO J
2936:
2929:321435
2926:
2893:
2858:
2823:
2788:
2781:164673
2778:
2735:
2700:
2693:139241
2690:
2647:
2640:310948
2637:
2593:
2583:
2526:
2491:
2483:
2436:
2395:
2387:
2349:
2341:
2297:
2249:
2241:
2188:
2180:
2071:
2064:311072
2061:
1904:FIP1L1
1877:, the
1667:rashes
1611:, and
1560:, and
1556:, the
1530:ligand
1526:3'-end
1490:, and
1435:PGDFRA
1426:FIP1L1
1413:uracil
1397:3' end
1369:FIP1L1
1358:PDGFRA
1354:FIP1L1
1350:PGDFRA
1346:3'-end
1342:FIP1L1
1338:5'-end
1295:PDGFRA
1289:PGDFRA
1283:FIP1L1
1250:FIP1L1
1248:. The
1226:FIP1L1
1202:FIP1L1
1195:FIP1L1
1183:FIP1L1
1181:(i.e,
1174:PAPOLA
1130:search
1128:PubMed
787:Q9D824
768:Q6UN15
664:Entrez
483:BioGPS
437:zygote
86:FIP1L1
78:134000
62:607686
45:FIP1L1
22:FIP1L1
3431:S2CID
3239:S2CID
2994:Blood
2838:Blood
2803:Blood
2489:S2CID
2459:(PDF)
2393:S2CID
2347:S2CID
2277:Blood
2247:S2CID
2186:S2CID
1609:STAT5
1605:NF-κB
1275:CHIC2
1230:exons
1178:CPSF1
697:66899
678:81608
657:Mouse
652:Human
623:Amigo
367:gonad
335:Mouse
328:Human
275:Start
210:Mouse
174:Start
107:Human
3423:PMID
3394:PMID
3345:help
3321:PMID
3311:ISBN
3282:PMID
3231:PMID
3194:PMID
3151:PMID
3108:PMID
3065:PMID
3012:PMID
2977:PMID
2934:PMID
2891:PMID
2856:PMID
2821:PMID
2786:PMID
2733:PMID
2698:PMID
2645:PMID
2591:PMID
2524:PMID
2481:PMID
2434:PMID
2385:PMID
2339:PMID
2295:PMID
2239:PMID
2178:PMID
2069:PMID
1908:RARA
1906:and
1875:RARA
1745:and
1405:CPSF
1377:RARA
1220:Gene
1212:and
1198:gene
1176:and
318:Bgee
266:Band
227:Chr.
170:4q12
165:Band
124:Chr.
58:OMIM
3415:doi
3384:PMC
3374:doi
3362:103
3303:doi
3272:PMC
3264:doi
3223:doi
3211:437
3184:PMC
3176:doi
3141:PMC
3133:doi
3098:PMC
3090:doi
3055:PMC
3045:doi
3033:101
3002:doi
2998:104
2967:PMC
2959:doi
2924:PMC
2916:doi
2881:doi
2846:doi
2842:103
2811:doi
2807:102
2776:PMC
2766:doi
2754:100
2723:doi
2719:348
2688:PMC
2678:doi
2635:PMC
2627:doi
2581:PMC
2573:doi
2516:doi
2471:doi
2467:176
2424:doi
2420:108
2377:doi
2329:doi
2285:doi
2281:129
2229:hdl
2221:doi
2168:doi
2164:144
2059:PMC
2051:doi
1828:FDA
1721:or
1717:or
1697:of
1669:or
1662:F/P
1439:or
1409:RNA
1399:of
1367:of
1348:of
1340:of
288:End
187:End
90:OMA
66:MGI
3452::
3429:.
3421:.
3411:24
3409:.
3392:.
3382:.
3372:.
3360:.
3356:.
3337::
3335:}}
3331:{{
3319:.
3309:.
3280:.
3270:.
3260:34
3258:.
3254:.
3237:.
3229:.
3221:.
3209:.
3192:.
3182:.
3172:79
3170:.
3166:.
3149:.
3139:.
3129:14
3127:.
3123:.
3106:.
3096:.
3086:14
3084:.
3080:.
3063:.
3053:.
3043:.
3031:.
3027:.
3010:.
2996:.
2992:.
2975:.
2965:.
2955:23
2953:.
2949:.
2932:.
2922:.
2912:24
2910:.
2906:.
2889:.
2877:36
2875:.
2871:.
2854:.
2840:.
2836:.
2819:.
2805:.
2801:.
2784:.
2774:.
2764:.
2752:.
2748:.
2731:.
2717:.
2713:.
2696:.
2686:.
2676:.
2666:99
2664:.
2660:.
2643:.
2633:.
2623:10
2621:.
2617:.
2589:.
2579:.
2569:96
2567:.
2563:.
2544:.
2522:.
2512:35
2510:.
2487:.
2479:.
2465:.
2461:.
2446:^
2432:.
2418:.
2414:.
2391:.
2383:.
2373:14
2371:.
2359:^
2345:.
2337:.
2325:90
2323:.
2319:.
2307:^
2293:.
2279:.
2275:.
2259:^
2245:.
2237:.
2227:.
2217:93
2215:.
2198:^
2184:.
2176:.
2162:.
2158:.
2134:^
2124:.
2106:.
2095:^
2067:.
2057:.
2047:11
2045:.
2041:.
2021:.
2003:.
1974:^
1953:^
1939:d)
1931:c)
1929:;
1920:b)
1916:a)
1886:,
1751:12
1742:12
1725:.
1705:;
1681:,
1673:;
1607:,
1578:c)
1566:b)
1564:;
1546:a)
1532:,
1486:,
1482:,
1478:,
1474:,
1451:.
1363:A
625:/
294:bp
281:bp
193:bp
180:bp
88:;
84::
80:;
76::
72:;
68::
64:;
60::
3437:.
3417::
3400:.
3376::
3368::
3347:)
3327:.
3305::
3288:.
3266::
3245:.
3225::
3217::
3200:.
3178::
3157:.
3135::
3114:.
3092::
3071:.
3047::
3039::
3018:.
3004::
2983:.
2961::
2940:.
2918::
2897:.
2883::
2862:.
2848::
2827:.
2813::
2792:.
2768::
2760::
2739:.
2725::
2704:.
2680::
2672::
2651:.
2629::
2597:.
2575::
2548:.
2530:.
2518::
2495:.
2473::
2440:.
2426::
2399:.
2379::
2353:.
2331::
2301:.
2287::
2253:.
2231::
2223::
2192:.
2170::
2128:.
2110:.
2089:.
2075:.
2053::
2025:.
2007:.
1635:/
1572:/
1437:)
1291:)
212:)
109:)
92::
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
